Sasisopin Kiertiburanakul

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9278450/publications.pdf

Version: 2024-02-01

331538 289141 1,970 127 21 40 g-index citations h-index papers 130 130 130 3025 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 2015, 12, e1001810.	3.9	188
2	Options for a Second-Line Antiretroviral Regimen for HIV Type 1-Infected Patients Whose Initial Regimen of a Fixed-Dose Combination of Stavudine, Lamivudine, and Nevirapine Fails. Clinical Infectious Diseases, 2007, 44, 447-452.	2.9	178
3	Cryptococcosis in human immunodeficiency virus-negative patients. International Journal of Infectious Diseases, 2006, 10, 72-78.	1.5	140
4	Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2015, 61, 1453-1461.	2.9	129
5	Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Research and Therapy, 2015, 12, 12.	0.7	82
6	Anti–IFN-γ autoantibodies are strongly associated with HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia. Journal of Allergy and Clinical Immunology, 2016, 137, 945-948.e8.	1.5	63
7	Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIVâ€positive patients. Journal of the International AIDS Society, 2014, 17, 18804.	1.2	56
8	Adherence to antiretroviral therapy for HIV in subâ€Saharan Africa and Asia: a comparative analysis of two regional cohorts. Journal of the International AIDS Society, 2017, 20, 21218.	1.2	56
9	Late Presentation into Care of HIV Disease and Its Associated Factors in Asia: Results of TAHOD. AIDS Research and Human Retroviruses, 2016, 32, 255-261.	0.5	42
10	Impact of Antiretroviral Therapy on the Relapse of Cryptococcosis and Survival of HIV-Infected Patients with Cryptococcal Infection. Current HIV Research, 2007, 5, 355-360.	0.2	41
11	Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. PLoS ONE, 2016, 11, e0150512.	1.1	40
12	Saliva sample pooling for the detection of SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 1506-1511.	2.5	30
13	Factors associated with acquired Anti IFN- \hat{I}^3 autoantibody in patients with nontuberculous mycobacterial infection. PLoS ONE, 2017, 12, e0176342.	1.1	30
14	Expert review on global real-world vaccine effectiveness against SARS-CoV-2. Expert Review of Vaccines, 2022, 21, 1255-1268.	2.0	30
15	Emergence of HIVâ€1 drug resistance mutations among antiretroviralâ€naÃ⁻ve HIVâ€1â€infected patients after rapid scaling up of antiretroviral therapy in Thailand. Journal of the International AIDS Society, 2012, 15, 12-12.	1,2	28
16	Emerging of HIV Drug Resistance: Epidemiology, Diagnosis, Treatment and Prevention. Current HIV Research, 2009, 7, 273-278.	0.2	27
17	SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM $1\ \text{study}$). American Journal of Transplantation, 2022, 22, 813-822.	2.6	27
18	Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV,the, 2016, 3, e343-e350.	2.1	26

#	Article	IF	CITATIONS
19	Diabetes mellitus burden among people living with <scp>HIV</scp> from the Asiaâ€Pacific region. Journal of the International AIDS Society, 2019, 22, e25236.	1.2	25
20	Long-Term Efficacy and Safety of First-Line Therapy with Once-Daily Saquinavir/Ritonavir. Antiviral Therapy, 2008, 13, 375-380.	0.6	25
21	Risk Factors for Nevirapine-Associated Rash Among HIV-Infected Patients with Low CD4 Cell Counts in Resource-Limited Settings. Current HIV Research, 2008, 6, 65-69.	0.2	24
22	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low―and middleâ€income countries: a multicohort study. Journal of the International AIDS Society, 2019, 22, e25392.	1.2	24
23	Tuberculosis in Antiretroviral Treatment Programs in Lower Income Countries: Availability and Use of Diagnostics and Screening. PLoS ONE, 2013, 8, e77697.	1.1	23
24	A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients. Antiviral Therapy, 2005, 10, 761-767.	0.6	23
25	Concomitant Tuberculous and Cryptococcal Thyroid Abscess in a Human Immunodeficiency Virus-infected Patient. Scandinavian Journal of Infectious Diseases, 2003, 35, 68-70.	1.5	22
26	Cryptococcuria as a manifestation of disseminated cryptococcosis and isolated urinary tract infection. Japanese Journal of Infectious Diseases, 2004, 57, 203-5.	0.5	20
27	A randomized controlled trial of sitafloxacin vs. ertapenem as a switchÂtherapy after treatment for acute pyelonephritis caused by extended-spectrum l²-lactamase-producing Escherichia coli : A pilot study. Journal of Infection and Chemotherapy, 2017, 23, 556-562.	0.8	19
28	Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. Journal of Clinical Virology, 2010, 47, 330-334.	1.6	18
29	Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. PLoS ONE, 2014, 9, e106525.	1.1	18
30	Serological diagnosis of pulmonary Mycobacterium tuberculosis infection by LIPS using a multiple antigen mixture. BMC Microbiology, 2015, 15, 205.	1.3	18
31	Clinical characteristics and risk factors for coronavirus disease 2019 (COVID-19) among patients under investigation in Thailand. PLoS ONE, 2020, 15, e0239250.	1.1	18
32	Microbial epidemiology and risk factors for relapse in gram-negative bacteria catheter-related bloodstream infection with a pilot prospective study in patients with catheter removal receiving short-duration of antibiotic therapy. BMC Infectious Diseases, 2020, 20, 604.	1.3	18
33	Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients. PLoS ONE, 2013, 8, e62057.	1.1	17
34	Pituitary tuberculoma: A consideration in the differential diagnosis in a patient manifesting with pituitary apoplexy-like syndrome. IDCases, 2016, 5, 63-66.	0.4	17
35	Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific. PLoS ONE, 2016, 11, e0161562.	1.1	17
36	Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients. Scientific Reports, 2022, 12, 3587.	1.6	17

#	Article	IF	CITATIONS
37	CD4:CD8 Ratio Comparison between Cohorts of HIV-Positive Asians and Caucasians upon Commencement of Antiretroviral Therapy. Antiviral Therapy, 2017, 22, 659-668.	0.6	16
38	Incidence of syphilis seroconversion among HIVâ€infected persons in Asia: results from the TREAT Asia HIV Observational Database. Journal of the International AIDS Society, 2016, 19, 20965.	1.2	15
39	Absence of Resistance Mutations in Antiretroviral-Naive Patients Treated with Ritonavir-Boosted Saquinavir. Antiviral Therapy, 2006, 11, 631-636.	0.6	15
40	Epidemiology of Bloodstream Infections and Predictive Factors of Mortality among HIV-Infected Adult Patients in Thailand in the Era of Highly Active Antiretroviral Therapy. Japanese Journal of Infectious Diseases, 2012, 65, 28-32.	0.5	15
41	Clinical Presentations of Newly Diagnosed HIV-Infected Patients at a University Hospital in Bangkok, Thailand. Journal of the International Association of Providers of AIDS Care, 2008, 7, 82-87.	1.2	14
42	HIV multiâ€drug resistance at firstâ€line antiretroviral failure and subsequent virological response in Asia. Journal of the International AIDS Society, 2014, 17, 19053.	1.2	14
43	A Multicenter Study of Clinical Presentations and Predictive Factors for Severe Manifestation of Dengue in Adults. Japanese Journal of Infectious Diseases, 2018, 71, 239-243.	0.5	14
44	Thai national guidelines for the prevention of mother-to-child transmission of human immunodeficiency virus 2017. Asian Biomedicine, 2017, 11, 145-159.	0.2	14
45	The influence of ageâ€associated comorbidities on responses to combination antiretroviral therapy in older people living with <scp>HIV</scp> . Journal of the International AIDS Society, 2019, 22, e25228.	1.2	13
46	Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region. Open AIDS Journal, 2017, 11, 52-66.	0.1	12
47	Effects of unplanned treatment interruptions on <scp>HIV</scp> treatment failure – results from <scp>TAHOD</scp> . Tropical Medicine and International Health, 2016, 21, 662-674.	1.0	11
48	Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine. Infectious Diseases and Therapy, 2022, 11, 351-365.	1.8	10
49	Monitoring of Renal Function among HIV-Infected Patients Receiving Tenofovir in a Resource-Limited Setting. Journal of the International Association of Providers of AIDS Care, 2011, 10, 297-302.	1.2	9
50	Current status of HIV treatment in Asia and the Pacific region. Sexual Health, 2014, 11, 119.	0.4	9
51	Early suboptimal ART adherence was associated with missed clinical visits in HIV-infected patients in Asia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1560-1566.	0.6	9
52	Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay. PLoS ONE, 2016, 11, e0147945.	1.1	9
53	Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2007, 90, 237-43.	0.4	9
54	High coverage and safety of influenza AÂ(H1N1) 2009 monovalent vaccination among health care personnel in Thailand. American Journal of Infection Control, 2011, 39, 525-528.	1.1	8

#	Article	IF	Citations
55	Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study. PLoS ONE, 2016, 11, e0157531.	1.1	8
56	Changes in renal function with longâ€term exposure to antiretroviral therapy in HIVâ€infected adults in Asia. Pharmacoepidemiology and Drug Safety, 2018, 27, 1209-1216.	0.9	8
57	A Nationwide Survey of Cytomegalovirus Prevention Strategies in Kidney Transplant Recipients in a Resource-Limited Setting. Open Forum Infectious Diseases, 2019, 6, ofz322.	0.4	8
58	Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. HIV Research and Clinical Practice, 2019, 20, 73-81.	1.1	7
59	Epidemiology and outcomes of dengue in kidney transplant recipients: A 20â€year retrospective analysis and comparative literature review. Clinical Transplantation, 2019, 33, e13458.	0.8	7
60	Infectious causes of acute meningitis among Thai adults in a university hospital. Journal of Infection and Chemotherapy, 2021, 27, 198-204.	0.8	7
61	Prevalence of Diabetes Mellitus in Patients with Tuberculosis: A Prospective Cohort Study. International Journal of Infectious Diseases, 2022, 116, 374-379.	1.5	7
62	Late and Low Compliance with Hepatitis B Serology Screening Among HIV-Infected Patients in a Resource-Limited Setting: An Issue to Improve HIV Care. Current HIV Research, 2011, 9, 54-60.	0.2	6
63	Clinical Characteristics of HIV-Infected Patients Who Survive after the Diagnosis of HIV Infection for More Than 10 Years in a Resource-Limited Setting. Journal of the International Association of Providers of AIDS Care, 2012, 11, 361-365.	1.2	6
64	Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV. Journal of the International AIDS Society, 2019, 22, e25264.	1.2	6
65	Anti–SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report. Kidney International, 2021, 100, 1136-1138.	2.6	6
66	The Impact of Timing of Antiretroviral Therapy Initiation on Retention in Care, Viral Load Suppression and Mortality in People Living with HIV: A Study in a University Hospital in Thailand. Journal of the International Association of Providers of AIDS Care, 2022, 21, 232595822210826.	0.6	6
67	The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand. Pharmacogenomics and Personalized Medicine, 2015, 8, 163.	0.4	5
68	Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratoryâ€based phenotypes among CRF01_AE and subtype B HIVâ€infected individuals. Journal of Medical Virology, 2016, 88, 234-243.	2.5	5
69	Validation of the D:A:D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 489-497.	0.9	5
70	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a costâ€effectiveness analysis. Journal of the International AIDS Society, 2020, 23, e25494.	1.2	5
71	Survival after Long-Term ART Exposure: Findings from an Asian Patient Population Retained in Care beyond 5 Years on ART. Antiviral Therapy, 2020, 25, 131-142.	0.6	5
72	Comparisons of Clinical Characteristics between Adult Patients with 2009 H1N1 Influenza and Those with Seasonal Influenza during the 2009 Epidemic in Thailand. Japanese Journal of Infectious Diseases, 2014, 67, 33-39.	0.5	4

#	Article	IF	CITATIONS
73	Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial. Open Forum Infectious Diseases, 2019, 6, ofz155.	0.4	4
74	Brief Report: Malignancies in Adults Living With HIV in Asia. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 301-307.	0.9	4
7 5	Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial. Current HIV Research, 2020, 18, 52-62.	0.2	4
76	Weight changes, metabolic syndrome and all ause mortality among Asian adults living with HIV. HIV Medicine, 2022, 23, 274-286.	1.0	4
77	Epidemiology of bloodstream infections and predictive factors of mortality among HIV-infected adult patients in Thailand in the era of highly active antiretroviral therapy. Japanese Journal of Infectious Diseases, 2012, 65, 28-32.	0.5	4
78	A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study. Pharmacogenomics and Personalized Medicine, 2015, 8, 155.	0.4	3
79	The occurrence of Simpson's paradox if site-level effect was ignored inÂthe TREAT Asia HIV Observational Database. Journal of Clinical Epidemiology, 2016, 76, 183-192.	2.4	3
80	The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the <scp>TREAT</scp> Asia <scp>HIV</scp> Observational Database (<scp>TAHOD</scp>). Journal of the International AIDS Society, 2017, 20, e25016.	1.2	3
81	Prevalence of HIV infection, access to HIV care, and response to antiretroviral therapy among partners of HIV-infected individuals in Thailand. PLoS ONE, 2018, 13, e0198654.	1.1	3
82	Influence of <i>CYP3A5</i> and <i>SLCO1B1</i> polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients. Pharmacogenomics, 2019, 20, 517-527.	0.6	3
83	HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asiaâ€Pacific region: a longitudinal cohort study. Journal of the International AIDS Society, 2021, 24, e25736.	1.2	3
84	Viral hepatitis and the cascade of care among people living with HIV in the Asiaâ€Pacific. HIV Medicine, 2022, 23, 959-968.	1.0	3
85	Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel. International Journal of Clinical Practice, 2022, 2022, 1-8.	0.8	3
86	Response to Screening of diabetes mellitus among people living with HIV – a comment on "Diabetes mellitus burden among people living with HIV from the Asiaâ€Pacific region―(Han etÂal. 2019). Journal of the International AIDS Society, 2019, 22, e25334.	1.2	2
87	Cardiovascular Disease Incidence Projections in the TREAT Asia HIV Observational Database (TAHOD). Antiviral Therapy, 2019, 24, 271-279.	0.6	2
88	Causes of Hospitalization and Death among Newly Diagnosed HIV-Infected Adults in Thailand. Journal of the International Association of Providers of AIDS Care, 2020, 19, 232595822091926.	0.6	2
89	Rama Co-RADS: Cutting-edge tool for improved communication in management and treatment of COVID-19 patients in Thailand. The Asean Journal of Radiology, 2021, 22, 29-49.	0.1	2
90	An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia. Antiviral Therapy, 2021, 25, 275-285.	0.6	2

#	Article	IF	Citations
91	A Model and Risk Score for Predicting Nevirapine-Associated Rash among HIV-infected Patients: In Settings of Low CD4 Cell Counts and Resource Limitation§. Open AIDS Journal, 2009, 3, 24-30.	0.1	2
92	Invasive aspergillosis in a tertiary-care hospital in Thailand. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2007, 90, 895-902.	0.4	2
93	A Multicenter Study of Clinical Presentations and Predictive Factors for Severe Manifestation of Dengue in Adults. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
94	Clinical manifestations of influenza and performance of rapid influenza diagnostic test: A university hospital setting. Health Science Reports, 2021, 4, e408.	0.6	1
95	Treatment modification after second-line failure among people living with HIV in the Asia-Pacific. Antiviral Therapy, 2021, 25, 377-387.	0.6	1
96	Clinical features of adult patients with a definite diagnosis of central nervous system tuberculosis in an endemic country: A 13-year retrospective review. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 21, 100190.	0.6	1
97	Attrition and treatment outcomes among adolescents and youths living with HIV in the Thai National AIDS Program. Journal of Virus Eradication, 2019, 5, 33-40.	0.3	1
98	Claw Hand Deformity: A Rare Complication of Herpes Zoster. Orthopedic Research and Reviews, 2021, Volume 13, 209-214.	0.7	1
99	Immune reconstitution inflammatory syndrome in HIV-infected patients with tuberculosis. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2010, 93, 257-64.	0.4	1
100	Patterns and prognosis of holding regimens for people living with HIV in Asian countries. PLoS ONE, 2022, 17, e0264157.	1.1	1
101	Optimal timing of antiretroviral therapy initiation in patients coinfected with HIV and tuberculosis. Expert Review of Clinical Pharmacology, 2011, 4, 143-146.	1.3	O
102	1569The effects of frequency of CD4 monitoring on clinical endpoints in clinically stable HIV-infected patients with viral suppression. Open Forum Infectious Diseases, 2014, 1, S418-S418.	0.4	0
103	P045â€Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults. Sexually Transmitted Infections, 2016, 92, A34.1-A34.	0.8	O
104	Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings. AIDS Research and Therapy, 2017, 14, 27.	0.7	0
105	Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Related Mortality. Open Forum Infectious Diseases, 2017, 4, S59-S59.	0.4	O
106	The Safety of Substitution of Antiretroviral Regimen in Non-Clinical Trial Settings in Asian Countries. Open Forum Infectious Diseases, 2017, 4, S432-S432.	0.4	O
107	1403. Infectious Causes of Acute Meningitis Among Thai Adults: A University Hospital Setting. Open Forum Infectious Diseases, 2019, 6, S510-S511.	0.4	O
108	1749. A Nationwide Survey of Cytomegalovirus Prevention Strategies in Kidney Transplant Recipients in a Resource-Limited Setting. Open Forum Infectious Diseases, 2019, 6, S641-S641.	0.4	0

#	Article	IF	CITATIONS
109	Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 436-443.	0.9	О
110	PS-SiZer map to investigate significant features of body-weight profile changes in HIV infected patients in the IeDEA Collaboration. PLoS ONE, 2020, 15, e0220165.	1.1	0
111	Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. PLoS ONE, 2021, 16, e0256926.	1.1	О
112	Impact of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/ritonavir trough concentrations in Thai HIV-infected patients. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-6.	0.0	0
113	Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients. Expert Review of Clinical Pharmacology, 2022, 15, 99-108.	1.3	0
114	Prediction Model of Pre-treatment HIV RNA Levels in Na \tilde{A} -ve Thai HIV-infected Patients: Application for Resource-limited Settings. Southeast Asian Journal of Tropical Medicine and Public Health, 2018, 49, 965-974.	1.0	0
115	Use of HIV Postexposure Prophylaxis in healthcare workers after occupational exposure: a Thai university hospital setting. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2006, 89, 974-8.	0.4	О
116	Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 $<$ 100 versus CD4 $>$ or = 100 cells/mm3. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2006, 89, 1381-7.	0.4	0
117	Title is missing!. , 2020, 15, e0220165.		0
118	Title is missing!. , 2020, 15, e0220165.		0
119	Title is missing!. , 2020, 15, e0220165.		0
120	Title is missing!. , 2020, 15, e0220165.		0
121	Title is missing!. , 2020, 15, e0220165.		0
122	Title is missing!. , 2020, 15, e0220165.		0
123	Title is missing!. , 2020, 15, e0239250.		0
124	Title is missing!. , 2020, 15, e0239250.		0
125	Title is missing!. , 2020, 15, e0239250.		0
126	Title is missing!. , 2020, 15, e0239250.		0

#	Article	IF	CITATIONS
127	MO191: Humoral Immune Response of theÂAdditionalÂChadox1 NCOV-19 Vaccine Following a Two-Dose Inactivated Whole-Virus SARS-COV-2 Vaccination in Patients on Dialysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0